Assertio Therapeutics
Newark
About Assertio Therapeutics
Depomed is a specialty pharmaceutical company that strives to put the patient first in all that they do. Its mission is to improve the lives of patients, families, physicians, providers, and payors by commercializing pain and neurology products and developing drugs for unmet medical needs. Depomed's Neurology and Pain Business currently markets three medicines focused on neuropathic pain and migraine, and it has an emerging Specialty Business focused on orphan drug indications and areas of unmet medical need.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $100K – $500K
- Total funding: $42.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2020)
- Ticker: nasdaq:DEPO
- Website: depomed.com
- Phone: 1-510-744-8000
Industries & Categories
Bioinformatics, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/assertio-therapeutics-204413 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.